Company Description
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally.
The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives.
In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health.
It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health.
Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
| Country | United States |
| Founded | 1952 |
| IPO Date | Feb 1, 2013 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 14,100 |
| CEO | Kristin Peck |
Contact Details
Address: 10 Sylvan Way Parsippany, New Jersey 07054 United States | |
| Phone | 973 822 7000 |
| Website | zoetis.com |
Stock Details
| Ticker Symbol | ZTS |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001555280 |
| CUSIP Number | 98978V103 |
| ISIN Number | US98978V1035 |
| Employer ID | 46-0696167 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kristin C. Peck | Chief Executive Officer and Director |
| Dr. Robert J. Polzer Ph.D. | Executive Vice President and President of Research and Development |
| Keith Sarbaugh | Executive Vice President and Chief Digital and Technology Officer |
| Steven Frank | Vice President of Investor Relations |
| Roxanne Lagano | Executive Vice President, General Counsel and Corporate Secretary |
| Julie A. Fuller | Executive Vice President, Chief Human Resources Officer and Global Operations |
| Jeannette Ferran Astorga | Executive Vice President of Corporate Affairs and Communications and Chief Sustainability Officer |
| Nick Ashton | Executive Vice President and President of Global Manufacturing and Supply |
| Jamie Brannan | Chief Commercial Officer |
| Rimma Driscoll | Executive Vice President and Head of Global Strategy, Commercial and Business Development and Global BioDevices |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | 8-K | Current Report |
| Dec 12, 2024 | 8-K | Current Report |
| Nov 25, 2024 | 144 | Filing |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 4, 2024 | 10-Q | Quarterly Report |
| Nov 4, 2024 | 8-K | Current Report |
| Oct 10, 2024 | 8-K | Current Report |
| Aug 6, 2024 | 10-Q | Quarterly Report |
| Aug 6, 2024 | 8-K | Current Report |
| Aug 1, 2024 | 8-K | Current Report |